Pharma Journalist -

Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an…
Read More...

Intellia Therapeutics, Inc. a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and…
Read More...

Pacira BioSciences, Inc. the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive…
Read More...

CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced the strategic decision to…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults…
Read More...

Silence Therapeutics plc a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with…
Read More...

Johnson & Johnson announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend…
Read More...

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create…
Read More...

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced a new strategic collaboration with Labcorp, a leading global life…
Read More...

Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced that it has signed a research collaboration and license option agreement with…
Read More...